References
- Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401
- Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell 2005;7:129-41
- Rosti G, Castagnetti F, Gugliotta G, et al. Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase. Crit Rev Oncol Hematol 2012;82:159-70
- Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9
- Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70
- Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company, 2011
- Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2011
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia v.1.2017. Available at: NCCN.org. [Last accessed: January 17, 2017]
- Breccia M, Molica M, Alimena G. How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review. Leuk Res 2014;38:1392-8
- Agostino NM, Chinchilli VM, Lynch CJ, et al. Effect of the tyrosine kinase inhibitors (sutinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract 2011;17:197-202
- Hughes T, le Coutre PD, Jootar S, et al. ENESTnd 5-year follow-up: continued benefit of frontline nilotinib vs imatinib in patients with CML in chronic phase. 19th Congress of the European Hematology Association. Milan, Italy, 12–15 June 2014
- Truven Health Analytics: Marketscan Research Databases. Available at: http://truvenhealth.com/your-healthcare-focus/analytic-research/marketscan-research-databases [Last accessed 30 May 2017]
- Iurlo A, Orsi E, Cattaneo D, et al. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem? Oncotarget 2015;6:33944-51
- Breccia M, Muscaritoli M, Gentilini F, et al. Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res 2007;31:1770-2
- Le Coutre T, Giles FJ, Hochhaus A, et al. Analysis of glucose profiles in imatinib-resistant or intolerant chronic myelogenous leukemia (CML) patients treated with nilotinib: lack of correlation between glucose levels and nilotinib efficacy. Blood 2007;110:4588
- Nicolini FE, Turkina A, Shen ZX, et al. Expanding nilotinib access in clinical trials (ENACT): an open-label multicenter study of oral nilotinib in adult patients with imatinib-intolerant Philadelphia chromosome-positive leukemia in the chronic phase. Cancer 2012;1118:118-26
- Breccia M, Loglisci G, Salaroli A, et al. Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index. Leuk Res 2012;36:e66-7
- Rea D, Mirault T, Cluzeau T, et al. Early onset hypercholesterolemia induced by the 2nd generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica 2014;99:1197-203